Carter Gould
Stock Analyst at Barclays
(3.43)
# 972
Out of 4,732 analysts
197
Total ratings
47.46%
Success rate
3.98%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Overweight | $160 → $165 | $143.26 | +15.18% | 12 | Dec 23, 2024 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $84 → $95 | $91.84 | +3.44% | 14 | Nov 7, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,080 → $1,065 | $681.58 | +56.25% | 19 | Nov 1, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $18 → $20 | $18.37 | +8.87% | 6 | Nov 1, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $1,025 → $975 | $725.72 | +34.35% | 11 | Oct 31, 2024 | |
| BIIB Biogen | Maintains: Equal-Weight | $190 → $180 | $140.55 | +28.07% | 24 | Oct 31, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $42 → $43 | $56.29 | -23.61% | 14 | Oct 7, 2024 | |
| MRK Merck & Co. | Maintains: Overweight | $142 → $140 | $97.92 | +42.97% | 10 | Oct 7, 2024 | |
| AMGN Amgen | Maintains: Equal-Weight | $300 → $315 | $272.11 | +15.76% | 16 | Oct 7, 2024 | |
| ABBV AbbVie | Maintains: Overweight | $200 → $212 | $171.56 | +23.57% | 14 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $75.84 | +31.86% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $3 | $1.33 | +125.56% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $32 | $26.30 | +21.67% | 14 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $1.04 | +188.46% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $2.89 | +211.42% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $45.74 | +107.70% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $31.46 | -36.43% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $66.48 | +9.81% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $1.5 → $1 | $0.86 | +16.89% | 4 | Jan 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.71 | +601.75% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $0.96 | +55.94% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.65 | +244.56% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $209.18 | +81.66% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $71.93 | +14.00% | 5 | Jan 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $183 → $188 | $422.00 | -55.45% | 1 | Jul 26, 2018 |
Neurocrine Biosciences
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $143.26
Upside: +15.18%
Gilead Sciences
Nov 7, 2024
Maintains: Equal-Weight
Price Target: $84 → $95
Current: $91.84
Upside: +3.44%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Overweight
Price Target: $1,080 → $1,065
Current: $681.58
Upside: +56.25%
Travere Therapeutics
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $18.37
Upside: +8.87%
Eli Lilly
Oct 31, 2024
Maintains: Overweight
Price Target: $1,025 → $975
Current: $725.72
Upside: +34.35%
Biogen
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $140.55
Upside: +28.07%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Underweight
Price Target: $42 → $43
Current: $56.29
Upside: -23.61%
Merck & Co.
Oct 7, 2024
Maintains: Overweight
Price Target: $142 → $140
Current: $97.92
Upside: +42.97%
Amgen
Oct 7, 2024
Maintains: Equal-Weight
Price Target: $300 → $315
Current: $272.11
Upside: +15.76%
AbbVie
Oct 7, 2024
Maintains: Overweight
Price Target: $200 → $212
Current: $171.56
Upside: +23.57%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $75.84
Upside: +31.86%
Aug 14, 2024
Maintains: Overweight
Price Target: $10 → $3
Current: $1.33
Upside: +125.56%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $30 → $32
Current: $26.30
Upside: +21.67%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $1.04
Upside: +188.46%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $2.89
Upside: +211.42%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $45.74
Upside: +107.70%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $31.46
Upside: -36.43%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $66.48
Upside: +9.81%
Jan 17, 2024
Maintains: Underweight
Price Target: $1.5 → $1
Current: $0.86
Upside: +16.89%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.71
Upside: +601.75%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.96
Upside: +55.94%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.65
Upside: +244.56%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $209.18
Upside: +81.66%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $71.93
Upside: +14.00%
Jul 26, 2018
Maintains: Neutral
Price Target: $183 → $188
Current: $422.00
Upside: -55.45%